Raghuveer Vedala, MD, is a clinical physician at the Norman Regional Health System.

Shagun Bindlish, MD, FACP, FOMA, DABOM, DACLM, is an internist and diabetologist with advanced expertise in obesity and lifestyle medicine. She serves as medical and scientific chair for the ADA Northern California and is the founder of the Golden State Obesity Society. An educator at Touro University California and University at Sea CME, she has trained providers worldwide in metabolic health. 

Recognized with the Obesity Medicine Association’s Outstanding Contribution Award in 2024, she is also nominated by her peers for the Compassionate Physician of the Year Award by the California Medical Association. Her work focuses on advancing diabetes and obesity care through innovation, education, and advocacy.

Pediatrics, Retention, and Lifestyle Changes in Obesity

The Obesity Medicine Association (OMA) Annual Conference 2026, in San Diego, California, featured >80 scientific and educational sessions covering everything from nutrition, physical activity, clinical pharmacology, and practice management for 

 care. From major steps forward in incretin therapies to the release of the updated OMA Obesity Algorithm, this year’s meeting brought tons of new data to the forefront of endocrinology care.

In the fifth and final episode of a 5-part 

, Raghuveer Vedala, MD, and Shagun Bindlish, MD, discuss the most impactful headlines to come out of OMA 2026 – as well as how these findings can be applied to everyday obesity management and treatment.

The discussion shifts to evolving approaches to pediatric and adolescent obesity management alongside broader shifts in how clinicians define treatment success. The speakers note that while off-label use of tirzepatide is being seen in adolescents, longer-term pediatric trial data are still pending, with expectations that more definitive evidence may emerge in the coming years. In contrast, currently approved therapies for adolescents include Wegovy and Saxenda (for ages 12 and older). A key theme is the reframing of success in obesity care: rather than focusing solely on scale-based targets, clinicians are encouraged to recognize meaningful clinical improvements—such as better blood pressure control, reduction in diabetes risk, improved sleep apnea, and enhanced overall function—even when weight loss is modest (e.g., 5–10%).

The speakers emphasize that weight plateaus are expected and reflect physiologic “set point” dynamics rather than treatment failure. They stress the importance of individualized expectations, avoiding overly restrictive eating patterns that may lead to nutritional deficiencies or unhealthy relationships with food, and instead prioritizing sustainable dietary habits, smaller balanced meals, and careful titration of therapy to manage side effects. In older adults, the discussion shifts further toward preserving lean mass and function, highlighting the need for assessments such as DEXA scanning, grip strength, gait speed, and structured resistance exercise to prevent sarcopenia and maintain independence while treating obesity.

Finally, the conversation broadens to a systems-level perspective on obesity care. GLP-1–based therapies are framed as tools that support behavior change rather than replacements for lifestyle foundations such as nutrition quality, physical activity, and a healthy relationship with food. The speakers underscore that success should ultimately be measured by improvements in quality of life and functional capacity—“making the immobile mobile”—rather than weight alone. They also highlight the impact of stigma and access barriers, noting that bias can influence physiology and that loss of coverage can undermine patients’ belief in recovery. Resources from the Obesity Medicine Association are recommended to support clinicians in adopting evidence-based, patient-centered obesity management approaches.

Videos

In the final segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity

GLP-1s in Conditions Beyond Obesity

The discussion centers on the expanding role of GLP-1 receptor agonists, particularly semaglutide, in obesity and related metabolic disease, and how recent clinical data are reshaping practice. A major focus is the ESSENCE trial in metabolic dysfunction–associated steatohepatitis (MASH), where semaglutide 2.4 mg demonstrated significant histologic benefit, with steatohepatitis resolution in roughly 63% of treated patients versus 34% with placebo. This has contributed to increased clinical confidence following accelerated regulatory action and updated guidance supporting GLP-1–based therapy in patients with obesity and MASH. The speakers emphasize that this is also helping unify care across specialties—endocrinology, hepatology, gastroenterology, and primary care—under a broader metabolic syndrome framework rather than siloed disease management.

Beyond weight loss, the conversation highlights emerging mechanistic insights suggesting GLP-1 therapies may exert direct cardiometabolic and anti-inflammatory effects. These include potential modulation of inflammatory pathways such as interleukin-6 signaling, which may help explain observed cardiovascular and renal benefits beyond what would be expected from weight reduction alone. At the same time, new safety considerations are discussed, including post-marketing signals related to psychiatric adverse events such as suicidality, which remain unconfirmed causally but are prompting closer monitoring and proactive patient counseling. Additional emerging adverse effects, such as dysesthesia and neuropathic-type sensations reported with higher-dose formulations, are also noted, reinforcing the importance of individualized risk–benefit assessment and surveillance.

The discussion then shifts to bariatric surgery as an enduring pillar of obesity treatment alongside pharmacotherapy. Updated BMI thresholds are reviewed (≥35 kg/m² regardless of comorbidity, or 30–34.9 kg/m² with metabolic disease), and the speakers emphasize that surgery remains highly effective, particularly for patients who do not tolerate or respond adequately to GLP-1 therapies. Practical perioperative considerations are highlighted, including evolving guidance on holding GLP-1 agents prior to surgery due to delayed gastric emptying and aspiration risk, as well as the potential role of preoperative liquid diets and point-of-care ultrasound assessment. Overall, the segment reinforces a patient-centered, multimodal approach in which medications, surgery, and lifestyle interventions are integrated rather than viewed as competing strategies.

In the fourth segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

OMA 2026 Recap: GLP-1s in Conditions Beyond Obesity

The Side Effects of GLP-1s for Obesity

Vedala shifts the discussion from emerging oral formulations of GLP-1 therapies to a key concern in obesity medicine: the impact of weight loss medications on lean mass, particularly muscle. The speakers highlight that while GLP-1–based therapies can produce substantial weight loss, a meaningful portion may come from lean mass, raising concerns about sarcopenia, frailty, bone health, and long-term functional outcomes, especially among older adults and women. Bindlish and Vedala discuss findings from studies such as SEMALEAN, which suggested that a significant percentage of weight loss with semaglutide may involve lean mass, while emphasizing that adequate protein intake and resistance training are essential strategies to help preserve muscle. Early data from the BELIEVE trial evaluating bimagrumab combined with semaglutide was also discussed as a potential future approach to improving fat loss while maintaining lean mass, though the evidence remains preliminary.

The conversation emphasizes that obesity treatment should not rely solely on medication, particularly as more GLP-1 therapies and other agents enter the market. The clinicians expressed concern that many patients are obtaining weight-loss medications through online platforms or compounded sources without receiving appropriate counseling on nutrition, exercise, muscle preservation, or baseline assessments such as body composition measurements. They stressed that medications should be viewed as tools that complement, rather than replace, lifestyle interventions. Resistance exercise, protein optimization, and comprehensive obesity medicine evaluations should become standard components of care to support long-term health, function, and longevity.

In the third segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

OMA 2026 Recap: The Side Effects of GLP-1s for Obesity

Oral Pharmacotherapy for Obesity

Vedala emphasizes that obesity treatment conversations require sensitivity, as many patients struggle to initiate discussions about weight due to stigma and fear. The speakers highlight concerns around discontinuation of GLP-1 therapies, noting that patients often experience significant anxiety about losing progress and regaining weight if coverage is interrupted. The conversation stresses the importance of clinician advocacy, including engagement with policymakers, to address access barriers and support long-term obesity management.

Vedala then shifts to emerging obesity pharmacotherapy, particularly the introduction of oral GLP-1 therapies and data from the ATTAIN trial. The speakers describe the newly approved oral, non-peptide GLP-1 medication as a potential shift in obesity treatment by offering an alternative to injectable therapies, with greater convenience and no fasting requirement. Trial data showed meaningful weight loss, with patients achieving an average reduction of around 11% and many reaching clinically important weight-loss thresholds. While injectable therapies such as tirzepatide and semaglutide remain the efficacy benchmarks, the availability of oral options may help address adherence, needle aversion, and access challenges.

Bindlish and Vedala then discuss how oral GLP-1 therapies may change the way clinicians approach obesity as a chronic disease, similar to other conditions managed with daily oral medications. The speakers note that patients appear increasingly receptive to oral options, but clinicians must continue educating patients about gastrointestinal side effects, which remain an important consideration. Because daily oral dosing may require more attention to meal timing, eating patterns, and symptom management, they emphasize the need for ongoing patient counseling as these therapies become more widely used.

In the second segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

OMA 2026 Recap: Oral Pharmacotherapy for Obesity

Defeating the Stigma of Obesity

The Obesity Medicine Association (OMA) Annual Conference 2026, in San Diego, California, featured >80 scientific and educational sessions covering everything from nutrition and physical activity to clinical pharmacology and practice management for 

, Raghuveer Vedala, MD, and Shagun Bindlish, MD, discuss the most impactful headlines from OMA 2026 – and how these findings can be applied to everyday obesity management and treatment.

Vedala and Bindlish highlight emerging obesity treatments, new GLP-1 data, management considerations in conditions such as MASH, and the evolving understanding of obesity care. They begin by emphasizing that advances in medications and clinical research must be paired with compassionate, patient-centered care. Bindlish focuses on weight stigma as a critical issue, noting that bias among healthcare professionals and internalized stigma among patients can significantly affect outcomes. She describes how stigma contributes to avoidance of care, worsening disease, and what conference presenters referred to as “therapeutic injustice,” where structural barriers and coverage limitations prevent patients from accessing effective treatments.

The discussion highlights that weight stigma is not merely an emotional concern but can have measurable physiological consequences, contributing to stress, metabolic dysfunction, and chronic disease burden. Bindlish shares examples of patients who experienced meaningful improvements with GLP-1 therapies but faced renewed uncertainty when medication coverage was lost, illustrating how access barriers can reverse progress and reinforce feelings of failure. The speakers emphasize that clinicians must advocate for patients by addressing prior authorization challenges, documenting clinical need, and engaging in policy efforts to improve access to obesity treatments.

Both experts call for healthcare professionals to recognize obesity as a chronic disease requiring both medical intervention and empathy. Vedala and Bindlish stress that awareness alone is insufficient; clinicians must actively challenge stigma, support equitable treatment access, and ensure that patients feel supported rather than blamed throughout their care journey.

In the first segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

OMA 2026 Recap: Defeating the Stigma of Obesity

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Articles

HCPLive previews Maui Derm NP+PA Summer 2026, covering sessions on atopic dermatitis, acne, psoriasis, pigmentation disorders, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Maui Derm NP+PA Summer 2026 Preview: 5 Sessions to Watch 

This segment of Lio's RAD Conference interview in Nashville highlights the growing number of therapeutics and an increasingly personalized approach.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Discussing Current Treatment Options for Atopic Dermatitis, With Peter Lio, MD

The CNP at Cleveland Clinic discusses how early recognition, cross-specialty collaboration, and extended patient engagement make APPs essential in the complex, long-term care of interstitial lung disease.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

APPs Uniquely Positioned in ILD Collaborative Care, With Jessica Glennie, MSN, APRN

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Panelists reached broad consensus that upfront dual oral combination therapy with an ERA and PDE5 inhibitor remains the foundational standard.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

PAH Expert Forum: Sotatercept, De-escalation, and the Limits of Upfront Therapy

Zobair Younossi, MD, MPH, is chairman of the Global NASH/MASH Council and professor and chairman of Beatty Liver and Obesity Research at Inova Health System.

EPL reduced hepatic steatosis vs placebo in EXCEL MASLD trial, meeting primary endpoint at 6 months by CAP FibroScan assessment.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatology

EPL Improves Steatosis, Fatigue in Patients With MASLD, With Zobair Younossi, MD

Peter Lio, MD, spoke at the RAD 2026 conference about the upcoming AAD pediatric guidelines for atopic dermatitis.

Upcoming AAD Pediatric Guidelines and Tips for Kids in Dermatology, With Peter Lio, MD

Michal Meron, MD, is an endocrinology fellow at the Albert Einstein College of Medicine.

Michal Meron, MD, discusses her recent study indicating the potential role of the TYG index in predicting liver disease among patients without diabetes with confirmed MASLD.

Triglyceride-Glucose Index Associated With Risk of End-Stage Liver Disease in MASLD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know

Experts review standard diagnostic criteria for diabetes, then detail phenotypic and clinical features that support—but do not definitively confirm—a diagnosis of type 2 diabetes, emphasizing the limitations of BMI-based assumptions.

Latest News

OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity

OMA 2026 Recap: GLP-1s in Conditions Beyond Obesity

OMA 2026 Recap: The Side Effects of GLP-1s for Obesity

OMA 2026 Recap: Oral Pharmacotherapy for Obesity

OMA 2026 Recap: Defeating the Stigma of Obesity